What is Aurinia Pharmaceuticals's accrued research and development expenses?

Aurinia Pharmaceuticals (AUPH) reported accrued research and development expenses of $4.79M in Q1 2026.

How has Aurinia Pharmaceuticals's accrued research and development expenses changed year-over-year?

Aurinia Pharmaceuticals's accrued research and development expenses increased by 16.4% year-over-year, from $4.12M to $4.79M.

Revenue$77.7M+24.4%

Gross profit$71.2M+32.1%

Operating income$41.4M+89.6%

Net income$34.4M+47.2%

EPS (diluted)$0.25+56.3%

Cash & equivalents$41.0M-38.3%

Total debt$85.2M-7.9%

Total equity$567.6M+62.1%

Total assets$724.0M+43.4%

Operating cash flow$32.6M+2,405%

Market cap$2.39B+78.5%

Gross margin89.7%+1.5pp

Operating margin41.7%+29.4pp

Net margin100%+83.9pp

Return on equity65%+53.8pp

Debt / equity0.2×-0.1×

Current ratio5.5×-0.4×

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept auph:AccruedResearchAndDevelopmentCurrent.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

What is Aurinia Pharmaceuticals's accrued research and development expenses?: Aurinia Pharmaceuticals (AUPH) reported accrued research and development expenses of $4.79M in Q1 2026.
How has Aurinia Pharmaceuticals's accrued research and development expenses changed year-over-year?: Aurinia Pharmaceuticals's accrued research and development expenses increased by 16.4% year-over-year, from $4.12M to $4.79M.